This is just a tiny glimpse of the data available to CivicScience clients. Discover more data.
CivicScience has data on more than 170K current GLP-1 users, providing a unique lens into these medications’ societal, cultural, and economic impact. As awareness and usage of the GLP-1 drugs continue to grow, we deliver monthly key data exploring how GLP-1 users are influencing a wide range of industries. Here’s a glimpse of our latest GLP-1 trend data – discover how you can access the full dataset here.
1. Cost and insurance coverage are the top reasons consumers say they aren’t taking a GLP-1 drug.
Very high list prices and unpredictable insurance coverage mean a person could pay less than $100 or more than $1K for a one-month supply. It’s the reason previous users are no longer taking a GLP-1 drug for weight loss, and the reason many haven’t started. Furthermore, close to half (49%) of current GLP-users cited moderate to severe medication side effects this month, but cost is still a greater deterrent for medication usage. This is an alarming sign for the GLP-1 industry as the impact of tariffs looms in an already uncertain market, affecting other areas of consumer spending, such as travel, for example.
Take our Poll: Have you ever considered using Ozempic (semaglutide) to lose weight?
2. GLP-1 users turn to chocolate over chips for snacking.
Chip snacking among GLP-1 users has been trending down for the past year, but has managed to stay ahead of chocolate – until this quarter. Whether it’s a post-Christmas or pre-Easter effect, chocolate became the primary snack choice for GLP-1 users during Q1 2025. Meat snacks and packaged cookies also made notable gains in Q1. In a similar vein, the number of GLP-1 users who anticipate spending more money on groceries has increased since our previous report.
Use this Data: CivicScience clients use data like this in real-time to track what specific segments prioritize and how those priorities change amid the increasingly uncertain economic climate. This allows them to refine their strategy to retain current customers and identify potential new customers where they’re most engaged.
3. Despite declining sharply among lookalike respondents, emotional well-being improved among current GLP-1 users this month.
Sadness, stress, and fear all dropped among GLP-1 users, and feelings of happiness remained far higher than the lookalike segment (U.S. adults with the same age and gender distribution who consider themselves overweight but are not using a GLP-1 medication). Current users are also notably less likely to report feelings of sadness and stress compared to the lookalike segment.
Let us Know: How are you feeling today?
Market uncertainty makes it more critical than ever to understand how your consumer base is thinking and feeling about the GLP-1 landscape. CivicScience’s GLP-1 consumer data provides invaluable insights into how these medications are transforming consumer behavior and influencing various industries in real-time. In order to thrive amidst market volatility and the gradual unfolding of a new normal, you need strategies to handle wide-ranging societal impacts across multiple industries. Join CivicScience Founder and CEO, John Dick, for a data-driven live webinar to explore how U.S. consumers are responding to financial pressures and what it means for your business strategy. Register for the webinar today by clicking here.
